Lineage Cell Therapeutics Inc (LCTX)vsVertex Pharmaceuticals Inc (VRTX)
LCTX
Lineage Cell Therapeutics Inc
$1.19
-1.65%
HEALTHCARE · Cap: $296.67M
VRTX
Vertex Pharmaceuticals Inc
$446.83
-1.60%
HEALTHCARE · Cap: $114.33B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 82571% more annual revenue ($12.22B vs $14.78M). VRTX leads profitability with a 35.5% profit margin vs 0.0%. VRTX appears more attractively valued with a PEG of 1.69. VRTX earns a higher WallStSmart Score of 68/100 (B-).
LCTX
Avoid24
out of 100
Grade: F
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.8%
Fair Value
$13.59
Current Price
$1.19
$12.40 discount
Margin of Safety
+52.4%
Fair Value
$949.55
Current Price
$446.83
$502.72 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LCTX
The strongest argument for LCTX centers on Debt/Equity. Revenue growth of 14.8% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : LCTX
The primary concerns for LCTX are EPS Growth, Market Cap, Profit Margin.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
LCTX profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
LCTX carries more volatility with a beta of 1.51 — expect wider price swings.
LCTX is growing revenue faster at 14.8% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (68/100 vs 24/100), backed by strong 35.5% margins. LCTX offers better value entry with a 86.8% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lineage Cell Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment of degenerative diseases in the United States and internationally. The company is headquartered in Carlsbad, California.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?